This series explores how geopolitical competition is transforming the pharmaceutical industry and what it means for Switzerland’s role in innovation, manufacturing and positioning as a global pharma hub.
Our latest episode:
More
Pharma pushes for higher European drug prices, Trump or no Trump
This content was published on
Pharmaceutical firms are still pressing Europe, including Switzerland, to raise drug prices despite limits to Trump’s Most-Favoured Nation plan.
China’s pharma companies turn to Europe for growth
This content was published on
China has become a pharma powerhouse, but local firms still face a steep climb toward financial stability and global growth.
Swiss non-profit drugmakers team up as funding shrinks
This content was published on
Waning commitments to global health causes and big pharma’s financial imperatives are threatening the development of innovative drugs to help patients left on the sidelines of medicine.
This content was published on
Drug development has always been expensive and risky, but now it’s measurably more so than a decade ago. Here are three reasons why.
Six charts show challenges facing Swiss pharmaceutical industry
This content was published on
The pharma industry is a mainstay of the Swiss economy and a global heavyweight. But the rise of new players could shake things up.
